Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
Related Questions
What is the preferred first-line non-insulin agent in patients with ketosis-prone diabetes during "remission" and evidence of preserved beta cell function?
What is the recommended approach to treating severe constipation in patients on GLP1 R agonist therapy?
Under what circumstances would you prioritize injectable semaglutide over oral semaglutide in patients with type 2 diabetes with atherosclerotic cardiovascular disease or chronic kidney disease?
How do you titrate the dose of an ACE inhibitor in a patient with type 1 diabetes mellitus who is normotensive but has moderately increased albuminuria?
How do you approach adjusting insulin pump settings in patients who have received intra-articular corticosteroid injections?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Should long-acting subcutaneous insulin be started upfront in addition to regular insulin infusion for patients with diabetic ketoacidosis?
